Premium
PRELIMINARY EVIDENCE OF A MOLECULAR PREDICTOR OF TAZEMETOSTAT RESPONSE, BEYOND EZH 2 MUTATION, IN NHL PATIENTS VIA CHARACTERIZATION OF ARCHIVE TUMOR AND CIRCULATING TUMOR DNA
Author(s) -
Blakemore S.J.,
Daigle S.R.,
McDonald A.A.,
Morschhauser F.,
Ribrag V.,
Salles G.,
McKay P.,
Tilly H.,
Schmitt A.,
Le Gouill S.,
Fruchart C.,
Radford J.,
Zinzani P.L.,
Assouline S.,
Cartron G.,
Dickinson M.,
Morin R.,
Wu H.,
Sausen M.,
Clawson A.,
Ho P.T.,
Miao H.
Publication year - 2017
Publication title -
hematological oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.918
H-Index - 44
eISSN - 1099-1069
pISSN - 0278-0232
DOI - 10.1002/hon.2438_14
Subject(s) - medicine , ezh2 , cancer research , oncology , clinical endpoint , mutation , gene , clinical trial , genetics , histone , biology